2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Sarcoma, Kaposi
3
Neoplasms
3
Breast Neoplasms
3
Acquired Immunodeficiency Syndrome
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
HIV Infections
2
Glioma
2
Glioblastoma
2
Endometrial Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Weight Loss
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Cancer, Papillary
1
Thrombocytopenia
1
Splenomegaly
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sezary Syndrome
1
Interventions
Rituximab
10
Valganciclovir
6
Etoposide
4
Doxorubicin
4
Valacyclovir
3
Gemcitabine
3
Dexamethasone
3
Cyclophosphamide
3
Cisplatin
3
spartalizumab
2
pembrolizumab
2
pegaspargase
2
Zidovudine
2
Vincristine
2
Radiotherapy, Intensity-Modulated
2
Prednisone
2
Methylprednisolone
2
Methotrexate
2
Matrix-M
2
Leucovorin
2
Lenalidomide
2
Cell Count
2
Carboplatin
2
Blood Specimen Collection
2
Acyclovir
2
valomaciclovir
1
toripalimab
1
threonic acid
1
ruxolitinib
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Epstein-Barr Virus Infections
×
Ritonavir
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn